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Abstract
Objective: A calcium antagonist, nifedipine, causes gin-
gival overgrowth as a side effect. It has been con-
firmed that the Japanese traditional medicine, Saireito,
inhibits the nifedipine-induced proliferation of gingi-
val fibroblasts in vitro. We performed an in vivo exper-
iment to determine whether Saireito has a therapeutic
use in the treatment of nifedipine-induced gingival
overgrowth.
Methods: The rats had significant gingival overgrowth
induced by the administration of nifedipine. The
space between the submandibular incisors and the
width of buccal gingiva of maxillary left first molar
were macroscopically measured. The buccal gingiva
was microscopically examined.
Results: Eight weeks after Saireito was administrated
together with nifedipine, Saireito decreased both the
incisor space and the gingiva width which had been
enlarged by nifedipine and furthermore, the area of
connective tissue of nifedipine + Saireito group was
significantly smaller than that of nifedipine alone.
Conclusion: In conclusion, Saireito may be clinically ef-
fective in therapy for calcium antagonist-induced gin-
gival overgrowth.
Key words: nifedipine, gingival overgrowth, Saireito,
therapy, rat
INTRODUCTION
Although there are many therapeutic drugs for the
treatment of hypertension, calcium (Ca2+) antagonists,
such as nifedipine, verapamil, and diltiazem, are fre-
quently used as quick-acting agents. Regrettably, how-
ever, Ca2+ antagonists cause gingival overgrowth as
a side effect by an increase in collagen and fibroblast
densities [1]. Since the detailed pathogenic mechanism
underlying gingival overgrowth remains unknown,
gingival overgrowth is treated surgically. Hence, the
development of treatment based on cause is urgently
needed.
Recently, as a result of an in vitro experiment, we
reported that the Japanese traditional medicine, Saire-
ito (Chai-Ling-Tang in Chinese) [2], or its main com-
ponent, Saiko [3], inhibits the proliferation of gingival
fibroblasts, the release of basic fibroblast growth fac-
tor (bFGF), and the synthesis of type I collagen. Saire-
ito is taken as a granulated drug with drinking water in
order to cure water diarrhea, acute gastroenteritis, ede-
ma and so on. This medicine is a powdery mixture of
dried extracts of 12 plants such as Bupleurum falca-
tum (17.5 %w/w), Pinellia ternate (12.5 %), Alisma
orientale (12.5 %), Scutellaria baicalensis (7.5 %), Zizy-
phus vulgaris (7.5 %) etc. [4]. In addition, the chemical
components of Saireito have been clarified by analysis
with HPLC and thereby, it is known that Saireito is
composed of many clinically active compounds, e.g.,
baicalin, oroxylin A, wogon, glycyrrhizin, and saikos-
aponin [4]. Thus, Saireito may be effective in therapy
for gingival overgrowth.
In the present study, an in vivo experiment was per-
formed to determine whether a Japanese traditional
medicine, i.e., Saireito, is useful in treating Ca2+ antag-
onist-induced gingival overgrowth.
MATERIALS AND METHODS
MACROSCOPIC EXAMINATION
Twenty-four male Wistar rats, 4 weeks of age and
weighing 80-88 g, were used (Fig.1A). At first, twelve
of the rats had significant gingival overgrowth induced
by the administration of nifedipine (250 mg/kg/day
po x 6 weeks), as previously described [5]. The 12 rats
were equally divided into two groups: 1) treatment with
nifedipine alone (n = 6) and 2) treatment with nifedip-
ine plus Saireito (n = 6). Saireito was administrated at a
dose of 500 mg/kg/day po [4, 6]. For administration
to the rats, a nifedipine solution (125 mg/ml) was
made by dissolving nifedipine powder in dimethyl su-
foxide (DMSO). A Saireito suspension (250 mg/ml)
was made by stirring Saireito powder in distilled water
for 24 hours at room temperature and was kept in a re-
frigerator (5 ǚC) until the administration.
The remaining 12 rats were administrated DMSO (2
ml/ kg/day po x 6 weeks) and therefore, served as the
nifedipine control group. These control rats were also
equally divided into two groups: 1) treatment with
DMSO alone (n = 6) and 2) treatment with DMSO
plus distilled water (H2O) (n = 6). The nifedipine con-
trol group was administered DMSO (4 ml/kg/day po),
while the nifedipine plus Saireito control group was
administrated DMSO (2 ml/kg/day po) plus H2O (2
ml/kg/day po). All 4 groups were provided a diet
(LabDiet 5053; Japan SLC, Shizuoka, Japan) and
drinking water ad libitum.
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rat gingiva after the Saireito treatment, under ether
anesthesia, the mandibular incisors and the buccal gin-
giva together with the maxillary left first molar were
photographed (E-330; Olympus, Tokyo, Japan) once
every 2 weeks. The space between mandibular incisors
was chosen for measurement since it has been report-
ed to increase with swelling of the gingiva [7]. When
photographing the molars, the mouth was opened by
two dental remedy wires. The images were enlarged
approximately 6 times by a computer (VY17F/DG-M;
NEC, Tokyo, Japan) and thereafter, the space between
the tips of the incisors and the width of the gingiva
were measured with a ruler (Fig. 1B).
MICROSCOPIC EXAMINATION
After an 8-week period of the Saireito treatment, the
maxillary left first molar with its surrounding tissues
were dissected under pentobarbital sodium (40 mg/kg
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Fig. 1. (A) Experimental design for Saireito therapy of
nifedipine-induced gingival overgrowth in rats. The numbers
in parentheses represent the number of rats used for each of
the experiments. (B) Measurements of incisor space and gin-
giva width. The space between the tips of the mandibular in-
cisors and the width of buccal gingival together with the max-
illary left first molar were measured as the incisor space and
the gingiva width, respectively. (C) Morphometric analysis of
gingival overgrowth. The area of an orange-colored part
(connective tissue) surrounded by a dotted line was mea-
sured.
Fig. 2. Effects of Saireito on nifedipine-induced gingival
overgrowth. Significant differences in incisor space and gingi-
va width between the nifedipine plus saireito and nifedipine
groups resolved 6 weeks after starting the Saireito administra-
tion. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001, n = 4 - 6.
Fig. 3. Macroscopic comparisons between the nifedipine
control (DMSO), nifedipine alone, and nifedipine plus saire-
ito groups. Saireito decreased both incisor spaces and gingiva
widths which had been increased by nifedipine. Arrow heads
represent the edge of buccal gingiva.
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diately fixed in 4 % paraformaldehyde fixative solu-
tion. The specimens were demineralized in 10 % ethyl-
enediaminetetraacetic acid (pH 7.4). The specimens
were then processed and embedded in paraffin.
Frontal-cut sections, 4 ﾵm in thickness, were pro-
cessed with a microtome. After consecutive sectioning,
the specimens were stained with hematoxylin-eosin
(HE) and azan, and observed by light microscopy.
Morphometric analyses were performed (Fig. 1C).
Cross sections of the molar were used for the histo-
logical examination of the maxillary molar buccal gin-
giva. The measured portion of the buccal gingiva is an
area surrounded by the basement membrane of gingi-
val epithelium, root surface and straight lines to be
perpendicular to the tooth axis via the upper end of
the alveolar bone. The buccal gingiva thickness was
observed with captured images of maxilla sections
stained with HE by using a microscopic-digital camera
system (model BX61- DP71, Olympus, Tokyo, Japan).
A stage micrometer was used for the calibration of
measurements. Each cross-sectional profile of speci-
mens obtained by using a magnification of x4 and rep-
resentative fields under x20 objective was pho-
tographed with a digital camera. All morphometric pa-
rameters were counted by light microscopy using im-
age analyzing computer program (Image-Pro Plus Ver.
4.5, Microsoft, WA, USA).
The rats were handled according to the Guiding
Principles for the Care and Use of Laboratory Ani-
mals, as approved by Matsumoto Dental University.
Nifedipine was purchased from Sigma (St. Louis,
MO, USA). Saireito (TJ-114) was a generous gift from
the Tsumura Co., Ltd. (Tokyo, Japan). DMSO and
ether were obtained from Nakalai Tesque Co., Ltd.
(Kyoto, Japan).
Data are expressed as the mean value ﾱ the stan-
dard error of the mean and the number of observa-
tions (n). Statistical analyses of the data were per-
formed by Student’s 2-sided simple t-test. Differences
between the mean values were considered significant if
the probability of error (p) was less than 0.05.
RESULTS
The incisor spaces and gingiva widths in the nifedipine
group were significantly increased in comparison with
the control group before administrating Saireito (data
not shown).
Figure 2 illustrates the statistical analyses of the
nifedipine control (DMSO), nifedipine, nifedipine plus
Saireito control (DMSO + H2O), and nifedipine plus
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Fig. 4. (A) Histopathologic fea-
tures of gingival specimens of the
DMSO, nifedipine, and nifedip-
ine plus Saireito groups. In HE-
stained specimens, it was con-
firmed that the nifedipine-in-
duced increase in the number of
fibroblasts was inhibited by
Saireito. In azan-stained speci-
mens, it was clearly observed that
Saireito decreased collagen for-
mation and inhibited vessel en-
largement. (B) The morphomet-
ric analyses of gingival over-
growth. There were significant
differences in the area of connec-
tive tissue between the nifedipine
and nifedipine plus Saireito
groups and between the DMSO
and nifedipine groups. *p<0.05,
***p<0.005, n = 3 (in each case)
5. Hattori:Umbruchvorlage  15.10.2009  12:39 Uhr  Seite 499Saireito groups. There were significant differences in
the incisor space and gingiva width 6 and 8 weeks after
starting the administration of Saireito, respectively;
these results indicated that Saireito clearly suppressed
nifedipine-induced gingival overgrowth. In addition,
there were significant differences between the nifedip-
ine and DMSO groups throughout the experiment.
Moreover, both of the differences in the incisor space
and gingiva width between the nifedipine plus Saireito
and its control (DMSO + H2O) groups resolved 6
weeks after starting the Saireito administration.
Figure 3 shows the comparison of incisor spaces and
gingiva widths between the DMSO, nifedipine alone,
and nifedipine plus Saireito groups. Eight weeks after
starting the Saireito administration, the addition of
Saireito to nifedipine inhibited both the increases in in-
cisor space and gingiva width induced by nifedipine
alone.
The histopathologic features of gingival specimens
in the DMSO, nifedipine, and nifedipine plus Saireito
groups are shown in Figure 4A. In HE-stained speci-
mens, there were obvious dimensional differences be-
tween the nifedipine and nifedipine plus Saireito
groups. Specifically, nifedipine induced a remarkable
increase in the number of fibroblasts and vessels,
which were inhibited by Saireito. The features were
clearly observed in azan-stained specimens. Saireito
decreased collagen formation and inhibited vessel en-
largement. On the other hand, in the DMSO, DMSO
plus H2O (specimen not shown), and nifedipine plus
Saireito groups, there were no histopathologic differ-
ences in the gingival connective tissue.
Figure 4B shows the morphometric analyses of gin-
gival overgrowth. There were significant differences in
the area of connective tissue between the nifedipine
and nifedipine + Saireito groups and between the
DMSO and nifedipine groups.
DISCUSSION
Saireito inhibits cell proliferation in mesangial cells [8]
and fibroblasts in idiopathic retroperitoneal fibrosis
[9]. However, the use of Saireito for therapy of gingi-
val overgrowth has not been reported. In the present
study, we have confirmed that Saireito is effective ther-
apy for nifedipine-induced gingival overgrowth in the
rat. Because the measurements (incisor space, gingiva
width, and connective tissue area) of the nifedipine
plus Saireito group were not less than the correspond-
ing measurements of the control group, we concluded
that the Saireito-induced inhibition of gingival over-
growth was not due to cytotoxicity. When Saireito in-
hibited nifedipine-induced gingival overgrowth, the
body weights (data not shown) of the nifedipine group
were significantly below the control group, while such
was not the case in the nifedipine plus Saireito group.
This finding indicated that the Saireito-induced effect
on gingival overgrowth was not attributable to either
nifedipine-induced hypertrophy or atrophy of the gin-
giva.
In in vitro experiments, Saireito inhibited nifedipine-
induced cell proliferation within 2 weeks [2], while in
in vivo experiments, Saireito inhibited gingival over-
growth in 6 or 8 weeks. Since there was a difference in
the methods used, the temporal difference in this ef-
fect may be caused by the difference of the Saireito
concentration acting on the gingival fibroblasts or by
the manner in which Saireito was partially metabolized
in the body. Since Saireito is an anti-inflammatory
agent that has saikosaponin and glycyrrhizin as main
components, it is not surprising that Saireito inhibited
the production and release of chemical mediators in
peripheral tissues. Hsu et al. [10] reported that saikos-
aponin D inhibited the growth of cells in the human
cancer cell line, A549. Matsumoto and Fujii [11] re-
ported that tenidap, an anti-inflammatory agent, inhib-
ited collagen synthesis in cultured human gingival fi-
broblasts. Thus, we propose that depression of both
bFGF exocytosis and collagen synthesis as a result of
steroidal effect of saikosaponin and glycyrrhizin in
gingival fibroblasts is involved in the characteristic
growth-inhibiting effect of Saireito.
From the present histopathologic studies, it has
been confirmed that nifedipine-induced gingival over-
growth results from proliferation of fibroblasts in the
buccal direction, as well as along the teeth, along with
an increase in collagen. The former response indicates
that the gingival sulcus is deepened. Morisaki et al. [12]
recentlyobserved the same phenomena. Since it was ob-
served that the associated vessels became enlarged and
increased in number, these actions may be related to
gingival overgrowth as well. Indeed, since nifedipine is
a Ca2+ channel blocker, it is not surprising that the ves-
sels became enlarged. In addition, Miura et al. [13] re-
ported that nifedipine induces angiogenesis in human
coronary arteries, thus supporting our observation.
Based on the findings reported herein, we conclude
that Saireito inhibits nifedipine-induced gingival over-
growth in vivo. Thus, Saireito may be clinically effective
in the treatment of Ca2+ antagonist-induced gingival
overgrowth.
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